diabetes close up
Subscribe to Diabetes Close Up (DCU). With a year's subscription, you'll receive:
- In-depth coverage of diabetes industry news and research trends
- Alerts on breaking news or important research
- Real time updates on conference proceedings
- Full access to our extensive archives
A LOOK INSIDE THE LATEST ISSUE OF DCU
Perhaps it was the bright California sunlight that streamed into the main hallway from the Yerba Buena gardens outside, or the simple joy of welcoming my friends in the diabetes world to my home city of San Francisco. Whatever it was, in my mind this was the best ADA Scientific Sessions in ages. Now that the dust has settled, we're pleased to bring you our annual ADA Download.
We hope you love this issue. Mark Yarchoan, Melissa Tjota, and I were privileged to interview Dr. Harold Lebovitz who chaired this year's Program Committee for the ADA - we were very lucky to get his take on all the data at the meeting. We also interviewed FDA patient advisor Rebecca Killion, who made some excellent points in representing patients at the recent (in our view, disturbing) FDA Advisory meeting in DC - our take on this meeting is also in this issue. In addition to all the diabetes updates, we have a special preview of the all-important AADE this August in DC!
Last, we published some key ADA survey results (n=150) in Closer Look, our real-time news service - please contact us if you don't receive this and are interested in doing so.
If you'd like to read more, then Subscribe to Diabetes Close Up.
IN-DEPTH INTERVIEWS WITH DIABETES AND OBESITY INSIDERS
DCU co-hosts with biotech expert Mike King a real-time discussion on ACCORD with noted endocrinologists Dr. Jay Skyler and Dr. Irl Hirsch. Read More
DCU talks to noted cardiologist Dr. Steven Nissen about Avandia. Read More
DCU talks to John Eng, who discovered Exenatide (exendin-4). Read More
DCU talks to Children With Diabetes founder Jeff Hitchcock about what industry does well and what it needs to do better. Read More
DCU talks to obesity expert Dr. Xavier Pi-Sunyer about clincial trials, prospects for new therapies, and his view of the "state of the state." Read More
DCU talks to Dr. Irl B. Hirsch about his thoughts on continuous glucose monitoring and glycemic variability, incretins, inhaled insulin, and how diabetes care in America is in a relative state of crisis. Read More
DCU talks to Dr. Zach Bloomgarden about the latest controversy with Galvus, the importance of rimonabant, the potential of continuous glucose monitoring, and much more. Read More
welcome!
New to Close Concerns?
Subscribe
Already registered?
Log in
WHAT WE DO
consulting
strategic advice and comprehensive information for those interested in the diabetes industry
diabetes close up
our monthly newsletter
industry reports
periodically we take the long view on trends or on specific breakthroughs.
TEAM
web log
Click here to view the entire Close Concerns weblog
Diabetes Roundup II
Read our eight page introduction to Diabetes Round Up II here
Close Concerns is pleased to announce Diabetes Roundup II, a unique 400+ page compilation of observations on the diabetes and obesity industries - a followup to our Diabetes Roundup I, published in 2004. Diabetes Round Up II features:
- In-depth reviews of the top eight academic diabetes conferences over the last 18 months (ADA, ADA Postgraduate Sessions, AADE, AACE, EASD, DTT, NAASO, the 1st Annual Amsterdam Diabetes Forum)
- Detailed insights on the dozen additional conferences of note (Canadian Diabetes Association; 1st International Conference on Pre-Diabetes and the Metabolic Syndrome; AIDPIT: Artificial Insulin Delivery Systems, Pancreas, and Islet Transplantation; ACE/AACE Consensus Conference on Inpatient Diabetes and Glycemic Control; and the Levine Symposium, among others)
- Detailed financial models for the $6 billion blood glucose monitoring and $1 billion insulin pump markets
- An-depth drug pipeline database of 50-plus companies developing nearly 200 diabetes and obesity therapies
- Our selection of the top 50 diabetes-related articles in medical journals over the last year (JAMA, NEJM, Diabetes Care, The Diabetes Educator) and detailed reviews of each
- Our reports on the major analyst meetings over the last 12-18 months (Animas, BMS, Lilly, Medtronic, Merck, Roche, Pfizer, Sanofi, Mannkind)
- A detailed calendar of 30 important upcoming diabetes meetings in 2006 and 2007
- The best of DCU: our top five stories from DCU #1 - #55
- The Close Concerns High Five Awards: our detailed assessment of the top five diabetes products introduced over the last 12-18 months, including Amylin's Symlin and Byetta, Insulet's Omnipod, and Dex Com's STS